INTRODUCTION {#s1}
============

Lung cancer is among the most common cancers in both man and woman, and is the leading cause of cancer-related death worldwide \[[@R1]\]. Non-small cell lung cancer (NSCLC), with two main histological types of adenocarcinoma and squamous-cell (epidermoid) carcinoma, accounts for about 80% of primary lung cancer, and a majority present with advanced stage (III/IV) when they were first diagnosed. Only 10--15% newly diagnosed NSCLC patients were adopted with a potentially curative resection \[[@R2]\]. Despite the introduction of targeted therapy on specific mutant molecules such as EGFR, platinum agents combined with another cytotoxic compound are still the first-line chemotherapy for advanced NSCLC. The action mode of platinating agents is known to bind the DNA with intra- or interstrand crosslinks and the Pt-DNA adduct lead to DNA lesions, activation of multiple pathways and result in cell apoptosis ultimately \[[@R3]\]. Despite efforts to improve therapeutic efficacy, the platinum-based chemotherapy brings modest benefits but also adverse effects, with the five-year survival rates less than 15%. And an increasing evidence showed that the limited efficacy for advanced NSCLC is due to drug resistance and toxicological side effects such as thrombocytopenia, nausea/vomiting, ototoxicity, nephrotoxicity and peripheral neurotoxicity, etc \[[@R3]\].

Mechanistically, therapeutic efficacy and response to platinum-based chemotherapy could be linked to these biological pathways, altered cellular accumulation, cytosolic inactivation of platinum drugs, inactivation of DNA repair pathway, altered apoptosis or increased tolerance to DNA damage \[[@R3]\]. The aberrant regulation and dysfunction of candidate genes in these pathway, which are largely ascribed to their functional polymorphisms, may influence interindividual differences in clinical outcomes. Thus there is a growing need toward tailoring chemotherapy to identify these functional genetic polymorphisms as predictive pharmacogenetic markers for better efficacy and minimal toxicity. To this end, the influence of sequence variants in pharmacodynamics pathways, such as nucleotide excision repair pathway, on clinical outcome has been extensively investigated \[[@R4]\]. In contrast, the biological function and clinical relevance of genetic polymorphisms in pharmacokinetics pathway for platinum metabolism and disposition are largely elusive.

Human SLC31A1 (solute carrier family 31 member 1) gene, also known as CTR1 (copper transporter 1), encodes a high-affinity copper transporter in cell membrane that functions as a homotrimer to effect the uptake of dietary copper. Recently, an interesting possibility has clearly emerged that the copper transporter SLC31A1 also acts as the major plasma-membrane transporter for platinum drug intake, including cisplatin, oxaliplatin and carboplatin \[[@R5]\]. Deletion of Slc31a1 in yeast and murine cells results in reduced cisplatin accumulation and increased resistance \[[@R6]\]. On the contrary, transfection of small cell lung cancer cell lines with SLC31A1 gene correlates with enhanced uptake of carboplatin and oxaliplatin \[[@R7]\]. Consistently, Slc31a1 knockout in murine model has also been shown to completely eliminate cisplatin tumor response *in vivo* \[[@R8]\]. Furthermore, in clinical setting, NSCLC patients with undetectable SLC31A1 expression in their tumors had reduced platinum concentration and tumor response, and lower platinum concentration in clinical specimens correlates directly with reduced tumor response and shorter survival time \[[@R9], [@R10]\]. Recently, in two pilot studies with relatively small sample size (two to three hundreds) in Chinese patients with NSCLC who received Pt-based therapy, Xu *et al.* documented that *SLC31A1* polymorphisms are associated with Pt-resistance or toxicity and poor clinical outcomes \[[@R11], [@R12]\]. But these results have not been validated in larger cohort of patients and functional implication of these associated variants are not clear.

In the present study, we assessed the association of tagging and potentially functional SNPs of *SLC31A1* gene with toxicological phenotypes, objective response and survivals of 1004 Chinese NSCLC patients receiving platinum-based treatment. We also functionally characterized a common variant at 3′ untranslated region (3′UTR) that modulates the microRNA-3′UTR interaction and decreases gene expression, proposing a possible underlying mechanism for the genetic association of *SLC31A1* with clinical outcomes.

RESULTS {#s2}
=======

Patient characteristics and clinical outcomes {#s2_1}
---------------------------------------------

A total of 1004 eligible NSCLC patients of Chinese population were recruited in the study to investigate the genetic association between *SCL31A1* polymorphisms and clinical outcomes of platinum-based chemotherapy. The main characteristics and clinical outcomes of patients are summarized in Table [1](#T1){ref-type="table"}. Ever smokers account for 57.5% of the patients. Adenocarcinoma was the most common histological type (62.9%). Severe gastrointestinal toxicity (nausea/vomiting) was observed in 8.3% of the evaluated patients (*n* = 964). Severe hematological toxicity was observed in 23.9% of the evaluated patients (*n* = 969), among which 29 (3.1%), 149 (15.2%), 115 (12.3%) and 34 (3.6%) patients suffered from grade 3 or 4 anemia, leukopenia, neutropenia, thrombocytopenia, respectively. Grade 3 or 4 overall toxicity was observed in 29.9% of the evaluated patients (*n* = 952). For survival analysis, by the time of final data collection (July 2012), the median follow-up time was 46.5 month, and death had occurred in 74.9% of enrolled patients. The median progression-free survival (PFS) was 9.1 months, and the median overall survival (OS) was 19.3 months. The rates of clinical phenotypes such as toxicities in our study were quite comparable to those previously reported in large randomized clinical trials \[[@R13]\].

###### Patient characteristics and clinical outcomes

  Characteristic                           Total Number   Number   Percent
  ---------------------------------------- -------------- -------- ---------
  All patients                             1004                    
  Sex                                      1004                    
  Male                                                    706      70.3
  Female                                                  298      29.7
  Age                                      1004                    
   ≤58                                                    518      51.6
   \>58                                                   486      48.4
  Smoking Status                           1000                    
   Ever Smoker                                            575      57.5
   Nonsmoker ^*a*^                                        425      42.5
  ECOG performance status ^*b*^            990                     
   0--1                                                   904      91.3
   2                                                      86       8.7
  TNM stage                                999                     
   IIIA                                                   81       8.1
   IIIB                                                   293      29.3
   IV                                                     625      62.6
  Histological type                        1004                    
   Adenocarcinoma (AC)                                    632      62.9
   Squamous cell carcinoma (SCC)                          221      22.1
   Adenosquamocarcinoma                                   20       2.0
   Others ^*c*^                                           131      13.0
  Chemotherapy regimens                    1004                    
   Platinum (cisplatin)-navelbine                         316      31.5
   Platinum (cisplatin)-gemcitabine                       239      23.8
   Platinum (carboplatin)-paclitaxel                      313      31.2
   Platinum-docetaxel                                     87       8.7
   Other platinum combinations                            49       4.9
  Objective response                       976                     
   Complete response (CR)                                 1        0.1
   Partial response (PR)                                  176      18.0
   Stable disease (SD)                                    611      62.6
   Progressive disease (PD)                               188      19.3
  Toxicity outcome                                                 
  Grade 3 or 4 gastrointestinal toxicity                           
   Nausea/vomiting                         964            80       8.3
  Grade 3 or 4 hematologic toxicity        969            232      23.9
   Anemia                                  944            29       3.1
   Leukopenia                              980            149      15.2
   Neutropenia                             935            115      12.3
  Thrombocytopenia                         950            34       3.6
  Grade 3 or 4 overall toxicity            952            285      29.9
  Median time to outcomes (months)         972                     
  Progression-free survival (PFS)                         9.1      
  Overall survival (OS)                                   19.3     

^*a*^ Nonsmokers were defined as those who had smoked \<1 cigarette per day and for \<1 year in their lifetime.

^*b*^ ECOG PS, Eastern Cooperative Oncology Group performance status.

^*c*^ Other carcinomas included mixed cell or undifferentiated carcinoma.

In the NSCLC patient cohort, we genotyped eight tagging and potentially functional SNPs of *SLC31A1* gene, three at 5′flanking region (rs4979223, rs4978536 and rs2233914), three at the intron (rs10817464, rs10981699 and rs10817465), and two at 3′UTR (rs10513202 and rs10759637), all of which were in Hardy-Weinberg equilibrium (HWE) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}), and six of which are common variants (minor allele frequency, MAF \>0.05) in this study population. The linkage disequilibrium analysis showed that the eight candidate SNPs could been partitioned into one haplotype block. For example, rs10759637 at 3′UTR are strictly associated with rs4979223 (*r*^2^ = 0.98) and rs2233914 (*r*^2^ = 0.56) at 5′flanking region (Figure [1A](#F1){ref-type="fig"}).

![rs10759637 in *SLC31A1* 3′UTR decreases microRNA-medicated gene expression\
(**A**) Schematic structure of *SLC31A1* gene and linkage disequilibrium of its candidate SNPs (color intensity is proportional to *D*′ and percent numbers represent *r*^2^). (**B**) Local sequence of *SLC31A1* 3′UTR annotated with the close locations of rs10759637 and two putative binding sites for hsa-miR-29 family. (**C**) Comparison of secondary structures, built with RNAfold program, of the local *SLC31A1* 3′UTRs harboring hsa-miR-29 binding sites and the wild or the variant alleles of rs10759637. (**D**) Luciferase reporter assays in 16HBE cells to analyze the regulatory role hsa-miR-29 on *SLC31A1* 3′UTR that could be modulated by rs10759637. Co-transfection with hsa-miR-29 member (a, b, or c) and *SLC31A1* 3′UTR construct consistently resulted in reduced luciferase activity. In the cases of hsa-miR-29 b or c, rs10759637 allelic state significantly affected the *cis*-regulation toward reporter expression. (**E**) Real-time quantitative RT-PCR analysis of *SLC31A1* mRNA expression in lung tumorous tissues from an independent cohort of patients, which was significantly correlated with rs10759637 genotypes.](oncotarget-09-23860-g001){#F1}

Association of SLC31A1 gene polymorphisms with toxicity and objective response {#s2_2}
------------------------------------------------------------------------------

In the patient cohort that had been evaluated for the seven toxicological phenotypes after platinum-based chemotherapy, we compared the genotypic distributions for the eight candidate SNPs of *SLC31A1* between groups with respective mild or severe toxicological outcomes ([Supplementary Table 2](#SD2){ref-type="supplementary-material"}). Interestingly, we observed that rs4979223 (*P* = 0.007), rs4978536 (*P* = 0.063, with marginal significance), rs2233914 (*P* = 0.039), rs10817464 (*P* = 0.006) and rs10759637 (*P* = 0.006) showed significantly divergent genotypic distribution between groups with mild or severe thrombocytopenia, some of which remained statistically significant after multiple test correction. Based on these five candidate SNPs, we then assessed the association between *SLC31A1* polymorphism and toxicological outcomes with multivariate unconditional logistic regression analysis (Table [2](#T2){ref-type="table"}). As to the tightly linked rs4979223 and rs10759637, we found their heterozygous genotype (A/C), as compared to the grouped homozygous genotypes (A/A+C/C), were significantly associated with severe thrombocytopenia, with ORs (95% CI) being 2.60 (1.20−5.64) and 2.69 (1.24−5.83), respectively. The variant containing genotype group (A/G+G/G) of rs4978536, as compared to the wild A/A, was also associated with severe thrombocytopenia (OR 2.59; 95% CI 1.23−5.47). In alike manner, the variant genotypes of rs10817464 were associated with increased risks of severe thrombocytopenia (OR 3.09; 95% CI 1.20−7.93), leucopenia (OR 2.16; 95% CI 1.19−3.92), hematologic toxicity (OR 1.98; 95% CI 1.19−3.29) and overall toxicity (OR 1.98; 95% CI 1.21−3.22). On the contrary. The variant A/A genotype of rs2233914, as referred to the wild allele containing genotypes (G/G+G/A), was associated with mild overall toxicity (OR 0.59; 95% CI 0.36−0.95).

###### Association between *SLC31A1* SNPs and toxicity outcomes

  ---------------------------------------------------------------------------------------------------------------------------------
  Reference SNP   Genotype           Toxicity               Toxicity grade\   *P* value^a^   OR (95% CI)^b^          *P* value^b^
                                                            (G3-4/G0-2)                                              
  --------------- ------------------ ---------------------- ----------------- -------------- ----------------------- --------------
  rs4979223       A/A                Thrombocytopenia       3/282             0.007 ^*c*^    1.00 (ref)              

                  A/C                                       24/417                           **4.90 (1.43−16.82)**   **0.012**

                  C/C                                       7/214                            3.00 (0.75−12.05)       0.121

                  A/C *vs* A/A+C/C                          10/496            0.004 ^*c*^    **2.60 (1.20−5.64)**    **0.015**

  rs4978536       A/A                Thrombocytopenia       20/701            0.063          1.00 (ref)              

                  A/G                                       13/195                           **2.71 (1.26−5.81)**    **0.010**

                  G/G                                       1/20                             1.63 (0.19−13.89)       0.654

                  A/G+G/G *vs* A/A                          14/215            0.018          **2.59 (1.23−5.47)**    **0.012**

  rs2233914       G/G                Overall toxicity       135/299           0.150          1.00 (ref)              

                  G/A                                       124/277                          0.88 (0.64−1.20)        0.409

                  A/A                                       26/91                            **0.55 (0.33−0.91)**    **0.020**

                  A/A *vs* G/G+G/A                          259/576           0.052          **0.59 (0.36−0.95)**    **0.029**

  rs10817464      A/A                Leucopenia             130/767           0.069          1.00 (ref)              

                  A/G                                       19/62                            **2.21 (1.22−4.01)**    **0.009**

                  G/G                                       0/2                              NA                      NA

                  A/G+G/G *vs* A/A                          19/64             0.041          **2.16 (1.19−3.92)**    **0.011**

                  A/A                Thrombocytopenia       27/842            0.006 ^*c*^    1.00 (ref)              

                  A/G                                       6/73                             2.75 (1.02−7.42)        0.045

                  G/G                                       1/1                              13.70 (0.69−220.29)     0.085

                  A/G+G/G *vs* A/A                          7/74              0.024          **3.09 (1.20−7.93)**    **0.019**

                  A/A                Hematologic toxicity   204/683           0.088          1.00 (ref)              

                  A/G                                       27/53                            **1.92 (1.15−3.21)**    **0.012**

                  G/G                                       1/1                              6.34 (0.36−110.34)      0.205

                  A/G+G/G *vs* A/A                          28/54             0.024          **1.98 (1.19−3.29)**    **0.008**

                  A/A                Overall toxicity       251/619           0.050          1.00 (ref)              

                  A/G                                       33/47                            **1.95 (1.19−3.19)**    **0.008**

                  G/G                                       1/1                              3.62 (0.20−66.75)       0.387

                  A/G+G/G *vs* A/A                          34/48             0.017          **1.98 (1.21−3.22)**    **0.006**

  rs10759637      A/A                Thrombocytopenia       3/286             0.006 ^*c*^    1.00 (ref)              

                  A/C                                       24/414                           **5.10 (1.49−17.52)**   **0.010**

                  C/C                                       7/216                            3.05 (0.76−12.24)       0.116

                  A/C *vs* A/A+C/C                          10/502            0.004 ^*c*^    **2.69 (1.24−5.83)**    **0.012**
  ---------------------------------------------------------------------------------------------------------------------------------

^*a*^ *P* values of Pearson χ^2^ tests for overall distributions for SNPs genotypes between severe and mild toxicological phenotypes.

^*b*^ Odds ratios (OR) and their 95% confidence intervals (CIs) and *P* values were calculated with unconditional logistic regression analysis, with adjustment of gender, age, smoking status, ECOG performance status, TNM status, histological types, and treatment regimen.

^*c*^ Statistical significance remained after multiple tests adjustment taking into account linkage disequilibrium between polymorphisms.

Because these five candidate SNPs of *SLC31A1* could be partitioned into one haplotype block (Figure [1](#F1){ref-type="fig"}), we also estimated their haplotype and diplotype frequencies in the cohort, and analyzed their association with toxicological outcomes (Table [3](#T3){ref-type="table"}). We predicted only four common haplotypes for the five SNPs in the 1004 individuals, which is consistent with their strong linkage disequilibrium. Agreeing with the genotype-based association results as above, the Hap4_CGGGC, which is composed of rs4979223-variant-C, rs4978536-variant-G, rs2233914-wild-G, rs10817464-variant-G and rs10759637-variant-C alleles, was significantly associated with severe toxicological outcomes such as leucopenia (OR 1.88; 95% CI 1.04−3.40), thrombocytopenia (OR 2.81; 95% CI 1.19−6.60), hematologic toxicity (OR 1.88; 95% CI 1.14−3.08) and overall toxicity (OR 1.89; 95% CI 1.17−3.06). As compared to non-Hap4 carrier diplotype, the Hap4 carrier diplotype was also consistently associated with these severe toxicological phenotypes, with ORs (95% CI) being 2.16 (1.19−3.92), 3.09 (1.20−7.93), 1.98 (1.19−3.29) and 1.98 (1.21−3.22), respectively.

###### Association between *SLC31A1* haplotype and diplotype and toxicity outcomes

  Haplotype or Diplotype a   Leucopenia   Thrombocytopenia       Hematologic toxicity   Overall toxicity                                                  
  -------------------------- ------------ ---------------------- ---------------------- ---------------------- --------- ---------------------- --------- ----------------------
  Haplotype frequency                                                                                                                                     
  Hap1_AAGAA                 164/880      1.00                   30/983                 1.00                   255/780   1.00                   311/702   1.00
  Hap2_CAAAC                 92/560       0.75 (0.57−1.00)       23/608                 0.97 (0.56−1.68)       142/500   0.79 (0.62−0.99)       176/459   0.77 (0.62−0.97)
  Hap3_CGGAC                 23/149       0.75 (0.46−1.23)       7/159                  1.37 (0.60−3.12)       37/133    0.83 (0.56−1.23)       47/118    0.88 (0.61−1.28)
  Hap4_CGGGC                 19/66        **1.88 (1.04−3.40)**   8/75                   **2.81 (1.19−6.60)**   29/55     **1.88 (1.14−3.08)**   35/49     **1.89 (1.17−3.06)**
  Hap5_others                0/7          NA                     0/7                    NA                     1/6       0.55 (0.06−4.91)       1/6       0.39 (0.04−3.51)
  Diplotype frequency                                                                                                                                     
  Non-Hap4 carriers          130/767      1.00                   27/842                 1.00                   204/683   1.00                   251/619   1.00
  Hap4 carriers              19/64        **2.16 (1.19−3.92)**   7/74                   **3.09 (1.20−7.93)**   28/54     **1.98 (1.19−3.29)**   34/48     **1.98 (1.21−3.22)**

^*a*^Haplotypes were predicted with PHASE basing on rs4979223 (A/C), rs4978536 (A/G), rs2233914 (G/A), rs10817464 (A/G) and rs10759637(A/C) that were associated with toxicity outcomes as shown in Table [2](#T2){ref-type="table"}.

^*b*^Odds ratios (OR) and their 95% confidence intervals (CIs) were calculated with unconditional logistic regression analysis, with adjustment of gender, age, smoking status, ECOG performance status, TNM status, histological types, and treatment regimen.

In the further stratification analysis by demographic and clinical characteristics (Table [4](#T4){ref-type="table"}), rs10759637 was associated in under-dominant model with thrombocytopenia in males (OR 5.08; 95% CI 1.62−15.94) and smoking patients (OR 4.06; 95% CI 1.40−15.11). Very similar association with thrombocytopenia was also observed for rs4979223. In alike manner, rs4978536 was associated in dominant model with thrombocytopenia in males (OR 3.16; 95% CI 1.18−8.47) and patients with adenocarcinoma (OR 3.05; 95% CI 1.26−7.37). Interestingly, in the subgroup patients with age ≤58 year or with TNM stage IV, rs10817464 consistently manifested significant association, in dominant model, with leucopenia, hematological toxicity, and overall toxicity, with ORs (95% CI) being 2.96 (1.26−6.96) and 2.88 (1.35−6.13), 2.27 (1.10−4.66) and 2.50 (1.31−4.76), 2.50 (1.25−4.96) and 2.56 (1.36−4.83), respectively. On the other hand, rs2233914 was associated with reduced overall toxicity in males (OR 0.63; 95% CI 0.44−0.90), patients treated with platinum-navelbine (OR 0.45; 95% CI 0.27−0.75) in dominant model, and in patients with adenocarcinoma (OR 0.41; 95% CI 0.21−0.81) in additive model. These data suggest that common variants of *SLC31A1* gene are associated with hematological toxicological outcomes of platinum-based chemotherapy for NSCLC patients.

###### Stratification analysis of association between *SLC31A1* SNPs and toxicity outcomes

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP (Wild/Variant, W/V)   Toxicity           Stratification subgroup   Genotype (WW−WV−VV)   Genetic model^a^        OR (95% CI)^b^          *P* value^b^                               
  ------------------------- ------------------ ------------------------- --------------------- ----------------------- ----------------------- ------------------ ----------------------- -----------
  rs4979223\                Thrombocytopenia   Gender                    Male                  2−15−2                  202−285−161             Under-DOM          4.93 (1.57−15.48)       0.006
  (A/C)                                                                                                                                                                                   

  Female                    1−9−5              80−132−53                 Under-DOM             1.22 (0.37−3.96)        0.744                                                              

  Smoking status            Smoker             2−13−2                    161−240−128           Under-DOM               **4.44 (1.35−14.59)**   **0.014**                                  

  Nonsmoker                 1−10−5             121−175−85                Under-DOM             1.74 (0.58−5.25)        0.327                                                              

  rs4978536\                Thrombocytopenia   Gender                    Male                  11−8−0                  507−133−11              DOM                **3.16 (1.18−8.47)**    **0.022**
  (A/G)                                                                                                                                                                                   

  Female                    9−5−1              194−62−9                  DOM                   1.86 (0.57−6.13)        0.305                                                              

  Histological type         AC                 14−10−1                   451−115−10            DOM                     **3.05 (1.26−7.37)**    **0.013**                                  

  SCC                       4−1−0              147−49−8                  DOM                   0.60 (0.06−6.53)        0.677                                                              

  rs2233914\                Overall toxicity   Gender                    Male                  90−71−21                208−207−70              DOM                **0.63 (0.44−0.90)**    **0.012**
  (G/A)                                                                                                                                                                                   

  Female                    45−53−5            91−70−21                  REC                   **0.28 (0.09−0.86)**    **0.026**                                                          

  Histological type         AC                 85−83−14                  182−181−60            ADD                     **0.41 (0.21−0.81)**    **0.010**                                  

  SCC                       26−24−4            80−56−20                  REC                   0.45 (0.13−1.61)        0.222                                                              

  Therapy regimens          Pt-navelbine       64−41−12                  64−77−29              DOM                     **0.45 (0.27−0.75)**    **0.002**                                  

  Pt-gemcitabine            18−42−6            82−65−20                  DOM                   **2.29 (1.19−4.42)**    **0.013**                                                          

  Pt-paclitaxe              35−21−5            119−97−24                 DOM                   0.69 (0.37−1.28)        0.233                                                              

  Pt-docetaxel              10−15−2            21−25−12                  ADD                   0.12 (0.01−1.73)        0.118                                                              

  rs10817464\               Leucopenia         Age                       ≤58                   56−10−0                 404−32−2                DOM                **2.96 (1.26−6.96)**    **0.013**
  (A/G)                                                                                                                                                                                   

  \>58                      74−9−0             363−30−0                                        1.49 (0.63−3.52)        0.369                                                              

  Smoking status            Smoker             72−12−0                   448−30−1              DOM                     **2.44 (1.10−5.38)**    **0.027**                                  

  Nonsmoker                 57−7−0             316−32−1                  DOM                   1.74 (0.66−4.58)        0.265                                                              

  TNM stage                 IIIA               7−3−0                     65−5−1                DOM                     24.55 (1.56−387.20)     0.023                                      

  IIIB                      36−2−0             224−24−0                                        0.59 (0.13−2.81)        0.509                                                              

  IV                        87−14−0            474−32−1                                        **2.88 (1.35−6.13)**    **0.006**                                                          

  Thrombocytopenia          Age                ≤58                       16−1−1                432−41−1                DOM                     1.13 (0.23−5.46)   0.879                   

  \>58                      11−5−0             410−32−0                                        **6.63 (1.81−24.26)**   **0.004**                                                          

  Hematologic toxicity      Gender             Male                      142−13−0              491−35−1                DOM                     1.31 (0.66−2.60)   0.447                   

  Female                    62−14−1            192−18−0                  DOM                   **4.19 (1.75−10.00)**   **0.001**                                                          

  Age                       ≤58                100−13−1                  357−28−1              DOM                     **2.27 (1.10−4.66)**    **0.026**                                  

  \>58                      104−14−0           326−25−0                                        1.78 (0.85−3.72)        0.126                                                              

  Smoking status            Smoker             111−13−0                  404−29−1              DOM                     1.48 (0.72−3.05)        0.289                                      

  Nonsmoker                 91−14−1            277−24−0                  DOM                   **2.49 (1.17−5.30)**    **0.018**                                                          

  TNM stage                 IIIA               10−4−0                    60−4−1                DOM                     7.60 (1.01−57.31)       0.049                                      

  IIIB                      57−4−0             201−21−0                                        0.74 (0.24−2.34)        0.612                                                              

  IV                        137−19−1           418−27−0                  DOM                   **2.50 (1.31−4.76)**    **0.006**                                                          

  Overall toxicity          Gender             Male                      167−15−0              451−33−1                DOM                     1.29 (0.66−2.49)   0.456                   

  Female                    84−18−1            168−14−0                  DOM                   **4.30 (1.81−10.23)**   **0.001**                                                          

  Age                       ≤58                124−17−1                  321−24−1              DOM                     **2.50 (1.25−4.96)**    **0.009**                                  

  \>58                      127−16−0           298−23−0                                        1.68 (0.82−3.44)        0.156                                                              

  Smoking status            Smoker             130−15−0                  373−27−1              DOM                     1.49 (0.74−2.99)        0.261                                      

  Nonsmoker                 117−18−1           246−20−0                  DOM                   2.39 (1.15−4.95)        0.020                                                              

  TNM stage                 IIIA               12−6−0                    57−2−1                DOM                     9.22 (1.49−57.07)       0.017                                      

  IIIB                      71−4−0             181−21−0                                        0.55 (0.18−1.71)        0.301                                                              

  IV                        168−23−1           377−23−0                  DOM                   **2.56 (1.36−4.83)**    **0.004**                                                          

  rs10759637\               Thrombocytopenia   Gender                    Male                  2−15−2                  207−284−160             Under-DOM          **5.08 (1.62−15.94)**   **0.005**
  (A/C)                                                                                                                                                                                   

  Female                    1−9−5              79−130−56                 Under-DOM             1.26 (0.39−4.06)        0.703                                                              

  Smoking status            Smoker             2−13−2                    165−238−128           Under-DOM               **4.60 (1.40−15.11)**   **0.012**                                  

  Nonsmoker                 1−10−5             121−174−87                Under-DOM             1.76 (0.59−5.30)        0.313                                                              
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^*a*^For each SNP, three different genetic models (dominant, recessive and additive) were analyzed, and the model with lowest *P* values was considered the best-fitting model. Under-dominant model was also analyzed for rs4979223 and rs10759637.

^*b*^Odds ratios (OR) and their 95% confidence intervals (CIs) and *P* values were calculated with unconditional logistic regression analysis, with adjustment of gender, age, smoking status, ECOG performance status, TNM status, histological types, and treatment regimen.

We also analyzed the association between *SLC31A1* polymorphism and chemotherapy objective response. None of the eight candidate SNPs of *SLC31A1* displayed statistically significant difference in genotypic distribution between the complete or partial response group and the stable or progressive disease group ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). These results do not support genetic correlation between *SLC31A1* and objective response of platinum-based chemotherapy in the patient cohort.

Association of SLC31A1 gene polymorphisms with survival {#s2_3}
-------------------------------------------------------

We measured genetic association of *SLC31A1* polymorphism with overall survival (OS) and progression-free survival (PFS) in the patient cohort with platinum-based chemotherapy by using log-rank test and Cox proportional hazards regression model (Table [5](#T5){ref-type="table"}). As to the OS dataset, the log-rank test showed that rs4979223 (*P* = 0.006), rs2233914 (*P* = 0.016) and rs10759637 (*P* = 0.010) were significantly associated with survival. The median OS time of patients with heterozygous A/C of rs10759637 was significantly shorter than those patients with homozygous A/A or C/C (17.7 *vs* 20.2, *P* = 0.004). Cox proportional hazards regression analysis further showed that rs10759637 A/C was associated with increased risk of disease progression as compared with the homozygous genotype group (HR 1.24; 95% CI 1.07−1.44). In alike manner, rs4979223 heterozygous genotype was also a risk factor for OS with HR of 1.25 (1.08−1.45) and log-rank *P* value of 0.002 when assuming under-dominant model. On the contrary, rs2233914 variant A/A homozygote, in recessive model, was a beneficial factor for OS with HR of 0.73 (0.58−0.92), the median OS time of patients A/A genotype was significantly longer than those with G/G or G/A genotypes (22.3 *vs* 18.8, log-rank *P* = 0.011). As to the PFS dataset, we did not observe any association between progression-free survival and the eight candidate SNPs of *SLC31A1*.

###### Association between *SLC31A1* SNPs and survival

                                  Overall survival   Progression-free survival                                                                                            
  ------------ ------------------ ------------------ --------------------------- ------- ----------------------- ----------- --------- ------ ------- ------------------- -------
  rs4979223    A/A                206/289            19.3                        0.006   1.00 (ref)                          174/271   7.5    0.292   1.00 (ref)          
               A/C                358/453            17.7                                1.18 (0.99--1.41)       0.069       257/416   9.1            0.86 (0.71--1.05)   0.143
               C/C                162/227            21.0                                0.88 (0.71--1.09)       0.236       126/207   10.3           0.83 (0.66--1.05)   0.126
               A/C *vs* A/A+C/C   368/516            20.0                        0.002   **1.25 (1.08--1.45)**   **0.004**   300/478   9.1    0.549   0.94 (0.79--1.11)   0.452
  rs4978536    A/A                551/733            19.4                        0.115   1.00 (ref)                          417/674   9.5    0.613   1.00 (ref)          
               A/G                163/218            17.6                                1.14 (0.95--1.36)       0.165       128/203   8.3            1.11 (0.91--1.36)   0.317
               G/G                14/21              29.2                                0.76 (0.45-1.31)        0.323       13/19     5.3            1.12 (0.64--1.97)   0.685
  rs2233914    G/G                326/448            19.1                        0.016   1.00 (ref)                          268/416   7.5    0.087   1.00 (ref)          
               G/A                315/403            18.6                                1.09 (0.92--1.27)       0.317       226/373   9.7            0.82 (0.69--0.99)   0.039
               A/A                87/121             22.3                                0.76 (0.60--0.97)       0.029       64/107    11.1           0.78 (0.59--1.03)   0.084
               A/A *vs* G/G+G/A   641/851            18.8                        0.011   **0.73 (0.58--0.92)**   **0.008**   494/789   8.7    0.200   0.86 (0.66--1.12)   0.269
  rs10817464   A/A                664/886            19.0                        0.520   1.00 (ref)                          515/817   9.1    0.467   1.00 (ref)          
               A/G                62/84              23.5                                0.89 (0.68--1.16)       0.391       42/77     9.7            0.83 (0.60--1.14)   0.249
               G/G                2/2                29.2                                1.32 (0.32--5.40)       0.703       1/2       3.1            0.61 (0.08--4.44)   0.626
  rs10981699   G/G                425/564            19.3                        0.821   1.00 (ref)                          317/515   9.5    0.264   1.00 (ref)          
               G/A                265/358            19.2                                0.94 (0.80--1.10)       0.449       209/334   8.1            1.04 (0.87--1.24)   0.708
               A/A                38/50              19.4                                0.96 (0.69--1.35)       0.832       32/47     6.3            1.29 (0.88--1.87)   0.192
  rs10817465   A/A                393/516            19.3                        0.482   1.00 (ref)                          292/475   9.2    0.437   1.00 (ref)          
               A/G                283/386            19.8                                0.98 (0.84--1.14)       0.782       222/355   9.2            1.02 (0.85--1.22)   0.830
               G/G                52/70              16.4                                1.11 (0.82--1.50)       0.516       44/66     6.6            1.21 (0.87--1.68)   0.260
  rs10513202   A/A                665/889            19.3                        0.664   1.00 (ref)                          501/817   9.3    0.085   1.00 (ref)          
               A/G                62/82              19.6                                1.03 (0.79--1.35)       0.825       56/78     6.1            1.27 (0.96--1.69)   0.094
               G/G                0/0                NA                                  NA                      NA          0/0       NA             NA                  NA
  rs10759637   A/A                209/293            19.3                        0.010   1.00 (ref)                          175/274   7.6    0.394   1.00 (ref)          
               A/C                356/450            17.7                                1.17 (0.98--1.40)       0.075       254/413   9.2            0.88 (0.72--1.07)   0.204
               C/C                163/229            20.9                                0.89 (0.72--1.10)       0.268       129/209   10.3           0.86 (0.68--1.09)   0.214
               A/C *vs* A/A+C/C   372/522            20.2                        0.004   **1.24 (1.07--1.44)**   **0.005**   304/483   9.1    0.520   0.94 (0.79--1.12)   0.479

^*a*^ Numbers indicate the death event for NSCLC patients during the following-up time among all individuals in the same genotype group.

^*b*^ MST: median survival time.

^*c*^ Hazard ratios (HR) and their 95% confidence intervals (CIs) and *P* values were calculated with by multivariate Cox proportional hazards regression with adjustment for covariates.

^*d*^ Numbers indicate patients who suffered of disease progression (including death) during the following-up time among all individuals in the same genotype group.

Notably, in further stratification analysis of survival data, rs4979223, rs2233914 and rs10759637 consistently manifested significant association in concordant stratification spectrum (Table [6](#T6){ref-type="table"} and Figure [2A--2F](#F2){ref-type="fig"}). Influence of rs10759637 heterozygous A/C genotype on OS were pronounced in male patients (log-rank *P* = 0.019; HR 1.23; 95% CI 1.04−1.47), patients older than 58 (log-rank *P* = 0.004; HR 1.38; 95% CI 1.10−1.73), ever smoker (log-rank *P* = 0.013; HR 1.28; 95% CI 1.05−1.55), patients with ECOG PS 0--1 (log-rank *P* = 0.005; HR 1.24; 95% CI 1.06−1.45), patients with squamous cell cancer (log-rank *P* = 0.010; HR 1.57; 95% CI 1.12−2.20), and patients treated with platinum-docetaxel (log-rank *P* = 0.013; HR 1.95; 95% CI 1.03−3.67), respectively. A very similar stratification spectrum with association signal was also observed for rs4979223. And also in the six subgroups of stratification, rs2233914 variant A/A homozygote, in recessive model, was beneficial modifier of OS with HRs (95% CI) being 0.75 (0.58−0.97), 0.74 (0.53−1.05), 0.73 (0.55−0.98), 0.76 (0.60−0.96), 0.38 (0.22−0.66) and 0.38 (0.17−0.87), respectively. These results clearly demonstrate that non-coding variants of *SLC31A1* are associated with overall survival of NSCLC patients with platinum-based chemotherapy.

###### Stratification analysis of association between *SLC31A1* SNPs and overall survival

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP (W/V,\         Stratification subgroup   Overall survival                                                                                                                        
  (Wild /Variant)                                                                                                                                                                      
  ------------------ ------------------------- ------------------ --------- --------- --------- ------ ------- ----------------------- ----------------------- ----------------------- -----------
  rs4979223 (A/C)    Gender                    Male               150/207   248/310   128/169   18.3   15.8    21.0                    0.034                   **1.26 (1.06--1.50)**   **0.009**

  Female             56/82                     110/143            34/58     25.1      21.4      20.3   0.049   1.19 (0.87--1.61)       0.274                                           

  Age                ≤58                       112/164            164/223   83/117    21.2      20.9   22.2    0.525                   1.12 (0.89--1.42)       0.346                   

  \>58               94/125                    194/230            79/110    19.1      15.2      20.0   0.003   **1.38 (1.10--1.74)**   **0.005**                                       

  Smoking status     Smoker                    121/166            211/261   99/134    18.3      15.3   21.5    0.026                   **1.29 (1.07--1.57)**   **0.009**               

  Nonsmoker          85/123                    144/189            62/92     21.7      20.9      20.3   0.176   1.16 (0.91--1.47)       0.244                                           

  ECOG PS            0-1                       189/265            316/404   150/209   19.7      17.7   21.0    0.010                   **1.26 (1.08--1.48)**   **0.003**               

  2                  13/19                     35/41              12/18     11.8      12.4      21.8   0.372   1.15 (0.62--2.14)       0.665                                           

  Histologic type    AC                        128/181            227/292   98/138    21.3      19.1   20.9    0.236                   1.13 (0.94--1.37)       0.204                   

  SCC                48/66                     75/92              37/53     16.6      13.1      22.2   0.022   **1.51 (1.08--2.12)**   **0.017**                                       

  Therapy regimens   Pt-navelbine              67/95              106/134   56/77     22.6      17.1   21.6    0.217                   1.31 (1.00--1.71)       0.047                   

  Pt-gemcitabine     40/62                     96/119             37/54     17.9      18.1      24.7   0.208   1.25 (0.92--1.72)       0.158                                           

  Pt-paclitaxe       78/102                    106/139            43/57     19.0      17.7      18.7   0.842   1.12 (0.85--1.48)       0.408                                           

  Pt-docetaxel       12/16                     34/40              18/27     15.9      17.4      24.3   0.013   **1.95 (1.03--3.67)**   **0.040**                                       

  rs2233914 (G/A)    Gender                    Male               231/308   226/286   71/95     17.9   17.2    22.3                    0.024                   **0.75 (0.58--0.97)**   **0.029**

  Female             95/140                    89/117             16/26     23.5      21.9      28.7   0.280   0.60 (0.34--1.08)       0.087                                           

  Age                ≤58                       170/243            146/201   43/61     21.2      20.4   24.8    0.265                   0.76 (0.53--1.09)       0.137                   

  \>58               156/205                   169/202            44/60     16.3      17.0      21.3   0.031   0.74 (0.53--1.05)       0.088                                           

  Smoking status     Smoker                    187/247            191/241   55/75     17.9      16.4   24.3    0.027                   **0.73 (0.55--0.98)**   **0.033**               

  Nonsmoker          139/201                   121/159            31/45     21.2      21.0      21.3   0.380   0.74 (0.50--1.09)       0.124                                           

  ECOG PS            0-1                       296/408            279/360   81/111    19.5      18.2   22.2    0.023                   **0.76 (0.60--0.96)**   **0.022**               

  2                  23/32                     32/38              6/10      12.4      19.1      22.3   0.431   0.67 (0.26--1.72)       0.401                                           

  Histologic type    AC                        196/275            204/262   54/75     20.2      19.6   21.3    0.484                   0.90 (0.67--1.21)       0.483                   

  SCC                81/107                    64/81              16/25     15.2      14.9      31.3   0.001   **0.38 (0.22--0.66)**   **0.001**                                       

  Therapy regimens   Pt-navelbine              100/142            96/119    33/45     19.5      17.2   22.2    0.263                   0.75 (0.51--1.11)       0.148                   

  Pt-gemcitabine     72/103                    83/106             19/27     17.9      19.8      28.7   0.231   0.67 (0.40--1.09)       0.108                                           

  Pt-paclitaxe       116/154                   89/119             23/27     19.4      18.0      16.5   0.352   1.37 (0.88--2.15)       0.164                                           

  Pt-docetaxel       23/29                     33/39              8/15      15.9      16.4      36.7   0.058   **0.38 (0.17--0.87)**   **0.021**                                       

  rs10759637 (A/C)   Gender                    Male               154/212   247/309   127/168   18.3   16.0    20.9                    0.059                   **1.23 (1.04--1.47)**   **0.019**

  Female             55/81                     109/141            36/61     25.8      21.4      20.3   0.057   1.22 (0.90--1.65)       0.193                                           

  Age                ≤58                       112/165            162/220   85/120    21.2      20.9   22.2    0.557                   1.13 (0.89--1.43)       0.321                   

  \>58               97/128                    194/230            78/109    19.1      15.3      19.3   0.006   **1.38 (1.10--1.73)**   **0.005**                                       

  Smoking status     Smoker                    125/170            209/259   99/134    18.3      15.7   21.5    0.035                   **1.28 (1.05--1.55)**   **0.013**               

  Nonsmoker          84/123                    144/188            63/94     22.4      20.9      20.2   0.223   1.17 (0.92--1.48)       0.210                                           

  ECOG PS            0-1                       191/267            316/403   149/209   19.7      17.7   20.4    0.016                   **1.24 (1.06--1.45)**   **0.007**               

  2                  14/21                     34/40              13/19     11.8      12.4      21.8   0.492   1.33 (0.75--2.38)       0.335                                           

  Histologic type    AC                        131/184            224/289   99/139    19.7      19.4   20.9    0.385                   1.10 (0.91--1.33)       0.307                   

  SCC                48/67                     76/93              37/53     19.0      13.6      22.2   0.017   **1.57 (1.12--2.20)**   **0.009**                                       

  Therapy regimens   Pt-navelbine              68/96              105/132   56/78     21.3      17.2   21.6    0.271                   1.29 (0.99--1.69)       0.063                   

  Pt-gemcitabine     42/64                     94/117             38/55     17.9      18.1      24.7   0.211   1.24 (0.91--1.70)       0.168                                           

  Pt-paclitaxe       78/103                    108/141            42/56     19.4      17.7      18.7   0.745   1.12 (0.85--1.47)       0.424                                           

  Pt-docetaxel       12/16                     34/40              18/27     15.9      17.4      24.3   0.013   **1.95 (1.03--3.67)**   **0.040**                                       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^*a*^Numbers indicate the death event for NSCLC patients during the following-up time among all individuals in the same genotype group.

^*b*^MST: median survival time.

^*c*^Log-rank tests for association between survival and overall genotypes.

^*d*^Hazard ratios (HR) and their 95% confidence intervals (CIs) and *P* values were calculated with by multivariate Cox proportional hazards regression with adjustment for covariates. Under-dominant, recessive and under-dominant models were used to estimate the HRs for the three SNPs, respectively. For rs4979223, A/C heterozygote was compared to A/A+C/C homozygotes as reference; For rs2233914, A/A homozygote was compared to G/G+G/A group as reference. For rs10759637, A/C heterozygote was compared to A/A+C/C homozygotes as reference.

![Kaplan-Meier curve of estimated overall survival for the NSCLC cohort according to *SLC31A1* polymorphisms\
In the entire patients (**A**) and subgroups stratified respectively with gender (**B**), age (**C**), smoking status (**D**), ECOG performance status (**E**), and histological type (**F**), the curves were plotted with SPSS software according to genotypes of two SNPs. For rs2233914, the A/A homozygote was compared to the G/G+G/A group as reference. For rs10759637, the A/C heterozygote was compared to the A/A+C/C homozygotes group as reference.](oncotarget-09-23860-g002){#F2}

rs10759637 at SLC31A1 3′UTR affects hsa-miR-29 mediated expression regulation {#s2_4}
-----------------------------------------------------------------------------

In this pharmacogenetic study, clinical outcomes such as severe thrombocytopenia hematological toxicity and overall survival of NSCLC patients with platinum-based chemotherapy were associated with linked non-coding variants of SLC31A1 gene that codes the transporter for platinum agent intake. We hypothesized that the underlying mechanism for the genetic association might be linked to functional interplay between polymorphic *cis*-elements and putative *trans*-acting factors such as transcription factor and microRNA. In order to identify putative microRNA targeting sequences in *SLC31A1* 3′UTR and assess potential effect of rs10759637 on microRNA-mediated regulation, we used the miRdSNP database and TargetScanHuman 6.2 program to screen potential microRNA binding sites at *SLC31A1* 3′UTR. Interestingly, as shown in Figure [1B](#F1){ref-type="fig"}, we predicted two putative binding sites, 314 bp upstream and 60 bp downstream to rs10759637, respectively, for the hsa-miR-29 family that was reported to be expressed in lung tissue and implicated in lung development and carcinogenesis \[[@R14], [@R15]\]. Further prediction of local secondary structure of *SLC31A1* mRNA 3′UTR with RNAfold program revealed that rs10759637 could alter the local mRNA secondary structure in the binding sites of hsa-miR-29abc by changing the minimum free energy from -133.40 kcal/mmol at the wild A allele state to -131.00 kcal/mmol at the variant C allele state (Figure [1C](#F1){ref-type="fig"}), suggesting that rs10759637 could modulate the regulatory function of hsa-miR-29 on *SLC31A1* 3′UTR. As to rs4979223 at 5′flanking region that was strictly associated with rs10759637, we did not observe putative binding sites containing it or other nearby linked SNPs in the 1000genome dataset for any transcription factor (data not shown). These results suggest that rs10759637 at *SLC31A1* 3′UTR might modulate the miRNA-mRNA interaction and affect miRNA-mediated expression regulation.

Using luciferase reporter gene assays in human bronchial epithelial cell line 16HBE, which, like lung epithelial cell, originates from primitive pluripotent pulmonary epithelial cells, we further investigated the functional modulation of rs10759637 on hsa-miR-29−*SLC31A1* 3′UTR interaction. In accordance with results of structural prediction as above, co-transfection with hsa-miR-29 member (a, b, or c) and *SLC31A1* 3′UTR construct (of rs10759637 A or C allele), as compared to the negative control microRNA mimic, consistently resulted in remarkably decreased luciferase activity, demonstrating that the hsa-miR-29 family is indeed a negative regulator for *SLC31A1* expression by targeting its 3′UTR. Interestingly, in the setting of cotransfection with hsa-miR-29 b or c, rs10759637 A/C at 3′UTR significantly affected the *cis*-regulation toward reporter expression, the variant C allele correlated with much lowered luciferase activity as compared to the wild A allele (Figure [1D](#F1){ref-type="fig"}, *P* \< 0.05). Finally, in lung tumorous tissues from an independent cohort of patients, we analyzed the correlation between rs10759637 genotypes and transcriptional expression level for *SLC31A1* using real-time quantitative RT-PCR. Consistent with the results of structure prediction and reporter assays, we found that, as compared with the wild A/A genotype, the heterozygous A/C (*P* = 0.018) and the A/C+C/C group (*P* = 0.014) were significantly correlated with lowered expression of *SLC31A1* transcript in lung cancer tissues, suggesting that the modulation of rs10759637 on hsa-miR-29−*SLC31A1* 3′UTR interaction observed in cell line has relevance in clinical samples.

Taken together, these functional studies revealed that rs10759637 in *SLC31A1* 3′UTR could modulate the microRNA-3′UTR interaction and thereby decrease gene expression, thus proposing a possible underlying mechanism for the genetic association between *SLC31A1* polymorphism and clinical outcomes of platinum-based chemotherapy in NSCLC patients.

DISCUSSION {#s3}
==========

In this multi-institutions based pharmacogenetic study of NSCLC patients with platinum-based chemotherapy, we found linked non-coding variants of *SLC31A1* gene, which encodes the major platinum uptake transporter, are associated with severe hematological toxicities such as thrombocytopenia and shorter overall survival. Further mechanistic analysis revealed that one SNP in 3′UTR correlated with downregulated gene expression through modulating the microRNA−3′UTR interaction. The clinically relevant and biologically functional *SLC31A1* polymorphism provides potential biomarker for outcome prediction of platinum-based chemotherapy and lung cancer management.

As a well-defined transporter for platinum import, the expression and function of SLC31A1 are involved in platinum disposition and clinical response to platinum-based chemotherapy. Chen *et al* reported that in a cohort of stage Ⅲ NSCLC patients in Chinese population receiving first-line platinum-based doublet chemotherapy, SLC31A1 protein overexpression is associated with better therapeutic response and better survival \[[@R16]\]. In a cohort of American patients who underwent neoadjuvant platinum-based chemotherapy, Kim *et al* also observed correlation between SLC31A1 expression in tumor size and tissue platinum concentration, undetectable protein expression and reduced drug load are associated with reduced tumor response and shorter survival time \[[@R9], [@R10]\]. Consistently, low levels of SLC31A1 mRNA are also associated with poor clinical response to platinum-based therapy in ovarian cancer patients \[[@R17]\]. These clinical studies demonstrate that the expression status *in situ* of SLC31A1 is a predictor for platinum-based therapy response and a significant prognostic factor for advanced NSCLC patients. However, the resectable cases only account for 10-15% of diagnosed NSCLC patients, and routine measure of SLC31A1 mRNA or protein expression in lung cancer tissues is not convenient. Thus, it is of very limited clinical utility for SLC31A1 expression as a putative biomarker of response and outcome for platinum-based chemotherapy in NSCLC patients. We here present evidences that rs10759637 in *SLC31A1* 3′UTR functionally decreased microRNA-mediated gene expression, and this common non-coding variants as well as linked SNPs were associated with severe hematological toxicities such as thrombocytopenia and shorter overall survival in the Chinese cohort of NSCLC patients with platinum-based chemotherapy. Notably, the genetic associations with survival were consistently pronounced in male patients, patients ever-smoking, older than 58, or with squamous cell carcinoma. Therefore, relevant variants of *SLC31A1* will be pertinent pharmacogenetic biomarkers, which is much more actionable than gene expression, for platinum-based therapy in NSCLC patients especially in these subgroups.

The association of rs10759637 in *SLC31A1* 3′UTR with clinical outcomes in NSCLC patients with platinum-based therapy is biologically plausible. In a screening *in silico* of potential interaction between microRNA and SNPs in 3′UTR of xenobiotic metabolism enzyme and transporter genes, Wei *et al* reported five putative miRNAs associated with rs10759637 of *SLC31A1* in liver \[[@R18]\]. However, we could not experimentally validate these results in reporter gene assays in 16HBE cells (data not shown). Interestingly, we predicted two putative binding sites near rs10759637 for hsa-miR-29 members, and the structure of local *SLC31A1* 3′UTR harboring these sites could be affected by rs10759637. Furthermore, the C allele, which was associated with poor outcomes of platinum-based therapy in NSCLC patients, correlated with reductions in luciferase activity in reporter assay and in *SLC31A1* transcript expression in clinical lung cancer tissues as well. Similarly, it was reported that one functional miRSNP, SNPs located at or near a microRNA binding site in 3′UTR of the target gene or in a microRNA, near the miR-24 binding site in the 3'UTR of dihydrofolate reductase gene (DHFR) interferes with miR-24 function, resulting in DHFR overexpression and methotrexate resistance \[[@R19]\]. A recent study also reported that the miRSNP rs1062980 may alter the expression of iron-responsive element binding protein 2 gene (IREB2) potentially through modulating the binding of miR-29a, and thereby modify risk of lung cancer \[[@R20]\]. The miR-29 family is expressed in lung tissues, and plays important roles in the pathogenesis of lung diseases by directly targeting genes such as those encoding extracellular matrix proteins and those associated with tissue invasion and metastasis in the contexts of fibrosis and adenocarcinoma, respectively \[[@R21], [@R22]\]. The regulation mechanism for *SLC31A1* expression is largely unknown, two transcription factors, Sp1 and hypoxia-induced factor 2α (HIF2α), have been shown to mediate its basal and inducible expression \[[@R23], [@R24]\]. We noticed that rs4979223 and rs2233914 at the at 5′flanking region of *SLC31A1* are not located at or near the *cis*-elements for Sp1 or HIF2α, their associations with toxicological phenotypes and survival could be largely due to their strong linkage disequilibrium with the functional rs10759637 at 3′UTR and genetic hitchhiking effect.

Therefore, the modulation of rs10759637 as miRSNP on miR-29−*SLC31A1* 3′UTR interaction not also proposes underlying mechanism for the association of *SLC31A1* polymorphism with clinical outcomes of platinum-based therapy, but also provides first evidence to link *SLC31A1* gene to the miR-29 regulatory network.

Another notable aspect of this study is that genotypes of rs10759637 and linked variants, as well as their combined haplotype and diplotype, were consistently associated with severe hematological toxicities especially thrombocytopenia. Thrombocytopenia is one of major common hematologic complications of cancer chemotherapy and is associated with increased morbidity, mortality and health care costs \[[@R25]\]. In a large cohort of solid patients (total *n* = 47159; NSCLC *n* = 7001) undergoing chemotherapy including platinum-based regimens (accounted for about 1/3 and were most common for NSCLC), NSCLC patients had the highest prevalence of severe thrombocytopenia (10.7%) cross the four major chemotherapy regimens, suggesting that the burden of thrombocytopenia remains high \[[@R26]\]. Although the precise mechanism for chemotherapy-induced thrombocytopenia is not well established, many cytotoxic agents including platinum are now known to cause thrombocytopenia by predominantly inducing apoptosis of the progenitors of megakaryocytes, the platelet precursor, at early stages of differentiation \[[@R27], [@R28]\]. As genetic evidence supporting this toxicological mechanism, a recent whole-exome sequencing study reported that severe thrombocytopenia in NSCLC patients treated with gemcitabine/carboplatin are associated with variant of DDX53 gene, a modulator of p53 mediated apoptosis \[[@R29]\]. Considering that platinum agents are intravenously administered, their biotransformation and dynamic distribution in the bloodstream are likely to be directly involved inducing hematologic toxicity. Because SLC31A1 is ubiquitously expressed in all tissues of vertebrates \[[@R30]\], part of administered platinum agents could be imported into all tissue cells including lung cancer cells as target, the other fraction remains bound with plasma protein in circulation \[[@R31]\]. In this scenario, we could cautiously postulate that, through interfering miRNA mediated expression, the naturally occurring germline SNP rs10759637 in *SLC31A1* 3′UTR might render reduced expression of transporter to all tissue cells, thus result in lowered platinum uptake in overall mass tissues, and accumulated platinum agents in bone marrow and peripheral blood plasma, and consequently be associated with platinum resistance of target tissue cells and hematologic toxicity such as thrombocytopenia.

We should cautiously point out that, in the study population of Chinese NSCLC patient cohort, we observed slight deviation from HWE for the genotypic distribution of two clinically relevant SNPs of *SLC31A1*, rs4979223 (*P* = 0.026) in 5′flanking region and rs10759637 (*P* = 0.011) in 3′UTR, with about 43 kb distance but nearly complete linkage disequilibrium, which was due to significant underrepresentation of their putatively disadvantageous heterozygotes in patients that were pharmacogenetically associated with poor outcomes such as severe thrombocytopenia and shorter survival. These HWE tests could be statistically well powered by the large sample of the patient cohort and the common allelic frequencies of the two SNPs \[[@R32]\]. However, in the SNP datasets for natural populations, we found that genotypic distribution of rs10759637 complies with HWE both in the overall global population (the 1000 genome dataset) and in Chinese Han population (the HapMap CHB dataset) (data not shown). The patient ascertainment was well defined, and the two common SNPs were of independent genotyping calling but are in nearly complete linkage disequilibrium. It is therefore at least possible that the HWE departure was due to ascertainment bias or genotyping errors, but instead, possible explanations could be sampling bias, underlying genetic model at the susceptibility locus, and other unknown factors in view of population genetics and demography \[[@R33]\]. Consistent with this scenario, rs10759637 manifested unique association with clinical outcomes in the NSCLC cohort with heterozygote disadvantage, which is also referred to as under-dominance, a genetic model where heterozygote has a lower overall fitness than either homozygote \[[@R34]\]. Although being rare cases, heterozygote disadvantage was also reported to account for the deviation from HWE of a common variant (c.677C\>T) of the 5,10-methylenetetrahydrofolate reductase gene (*MTHFR*) in subfertile patients and its association with embryo aneuploidy \[[@R35]\]. However, the biological mechanism by which the *SLC31A1* rs10759637 A/C heterozygote could be disadvantage is unclear, especially considering that the variant C allele correlated with diminished gene expression. Furthermore, it has been reported of remarkable divergence in *SLC31A1* expression *in situ* as well as related drug disposition and response among populations with different ethnic ancestry. In the cohort of NSCLC patients in American population who underwent neoadjuvant platinum-based chemotherapy, Kim *et al.* reported that the African American had significantly reduced SLC31A1 expression in tumor (*P* = 0.001), lowered tissue platinum concentration (*P* = 0.009) and decreased tumor shrinkage (*P* = 0.016) as compared to Caucasians \[[@R9]\]. We also noticed that, in public SNP database, the low-expression-related C allele of rs10759637 is the ancestral allele that is common in African population, the high-expression-related A allele is the derived allele that is dominant in Caucasian and Chinese Han population, suggesting of significant population differentiation at this locus. These observations not only support the function mode of rs10759637 on *SLC31A1* expression, but also provide comparative and evolutionary pharmacogenetics implications for the association of *SLC31A1* polymorphism with clinical outcomes of platinum-based chemotherapy in lung cancer.

In summary, this pharmacogenetic study on advanced NSCLC patients with platinum-based chemotherapy has identified linked variants of platinum import transporter *SLC31A1* gene that were associated with severe hematological toxicities such as thrombocytopenia and shorter survival, one of which decreased gene expression through modulating microRNA-3′UTR interaction. Given that platinum-based chemotherapy is routinely used in clinical management of many types of cancers, and SLC31A1 is ubiquitously expressed in human tissues, validation of these findings in cohorts of lung cancer and other relevant types of cancer with larger sample size would be warranted in different ethnic populations.

MATERIALS AND METHODS {#s4}
=====================

Patient recruitment and follow-up {#s4_1}
---------------------------------

This study encompassed in total 1004 eligible patients (Chinese Han) histologically diagnosed with stage III-IV NSCLC between March 2005 and January 2010 from five hospitals in the East of China: Shanghai Chest Hospital, Shanghai Zhongshan Hospital, Shanghai Changhai Hospital, Shanghai Changzheng Hospital, and Cancer Hospital of Jiangsu Province. The recruitment criteria for enrolling eligible patients and their demographic characteristics such as gender, age at diagnosis, smoking status, ECOG performance status, clinical TNM stage, and tumor histological type were described in detail in our previous reports \[[@R36]--[@R39]\]. No statistically significant difference was observed in the distribution of demographic features among the patients from the six hospitals (*P*~gender~ = 0.698, *P*~age~ = 0.321). In addition, previously prepared lung cancer tissues from 47 surgically resectable patients recruited at Shanghai Changzheng Hospital were used for gene expression analyses \[[@R40]\].

The patients enrolled in the pharmacogenetic study were inoperable and received first-line, platinum-based chemotherapy (no prior surgery, radiotherapy, or concurrent chemoradiotherapy). The chemotherapeutic regimens were as follows: either cisplatin (75 mg/m^2^) or carboplatin (at an area under the curve 5), both administered on day 1 every 3 weeks, in combination with navelbine (25 mg/m^2^) on days 1 and 8 every 3 weeks, or gemcitabine (1250 mg/m^2^) on days 1 and 8 every 3 weeks, or paclitaxel (175 mg/m^2^) on day 1 every 3 weeks, or docetaxel (75 mg/m^2^) on day 1 every 3 weeks. A few patients received other platinum-based treatment (*n* = 49). All chemotherapeutic drugs were administered intravenously, and all treatments lasted for 2 to 6 cycles.

Clinical outcomes including toxicities, responses and survival were assessed in this study. The incidence of grade 3 or 4 chemotherapy toxicity was assessed for the patients from the end of the first two cycles of treatment according to the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0), including overall toxicity, gastrointestinal toxicity (nausea and vomiting), and hematologic toxicity (leucopenia, neutropenia, anemia, and thrombocytopenia) \[[@R41]\]. No grade 5 toxicity (death) was observed. Responses to platinum-based chemotherapy were evaluated after the first two cycles of the course, which are classified into four categories namely complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.0 \[[@R42]\]. Object response rate (ORR) is defined as the percentage of patients with CR or PR. Survival data were collected from several sources including follow-up calls, the Social Security Death Index, and clinical medical records of inpatient and outpatient. Progression-free survival (PFS) was calculated from the date of chemotherapy beginning to the date of disease progression or death (whichever occurred first) or the last progression-free follow-up. Overall survival (OS) was calculated from the date of chemotherapy beginning to the date of death. The research assistants who performed the genotyping assays were blinded to the clinical state of patients and the clinical investigators were blinded to the genotypic state of patients. The study protocol was approved by the Ethical Review Committees of Fudan University School of Life Sciences and the participating hospitals, and written informed consent was obtained from each subjects.

SNPs selection and genotyping {#s4_2}
-----------------------------

Eight polymorphisms were selected by an approach combining both tagging and potentially functional SNPs of *SLC31A1* gene. The tagging SNPs were screened from the Han Chinese in Beijing (CHB) population dataset of the HapMap database (<http://www.hapmap.org>) using a minor allele frequency (MAF) cutoff of 0.05 and a correlation coefficient (*r*^2^) threshold of 0.8. Genomic DNA was extracted from whole blood using the QIAamp DNA Maxi Kit (Qiagen GmbH, Hilden, Germany). Genotyping was performed using iSelect HD BeadChip (Illumina, San Diego, CA, USA) with the following quality-control criteria: genotyping call rate of SNP \>0.95, GenCall score \>0.2, and *P* value of Hardy-Weinberg equilibrium (HWE) \>0.01. Genotyping of one SNP (rs10759637) at the 3′UTR for lung cancer tissues of the 47 surgically resectable patients was conducted using PCR-direct sequencing with forward primer 5′-GGAGAGCAAGGAATGTGGACT-3′ and the reverse primer 5′-GCAGCTCATGCTGAGATTTCTA-3′.

*In silico* prediction of microRNA binding sites at the 3′UTR of *SLC31A1* {#s4_3}
--------------------------------------------------------------------------

In order to identify putative microRNA targeting sequences in *SLC31A1* 3′UTR, and assess potential effect of rs10759637 on microRNA-mediated regulation, we used the miRdSNP database (<http://mirdsnp.ccr.buffalo.edu/index.php>) and TargetScanHuman 6.2 program (<http://www.targetscan.org/>) to screen microRNA binding sites, and used RNAfold (<http://rna.tbi.univie.ac.at/>) to predict the local secondary structure of the *SLC31A1* mRNA.

Luciferase reporter assays {#s4_4}
--------------------------

We performed luciferase reporter assays to characterize the effect of rs10759637 at *SLC31A1* 3′UTR on microRNA-mediated regulation. We constructed reporter gene vectors for rs10759637 by amplifying the target sequence about 1200bp around rs10759637 at *SLC31A1* 3′UTR from human genomic DNA, with the forward primer 5′-CCGCTCGAGTCTACCAGTCATGGGCCAGAAGG-3′ and the reverse primer 5′-ATTTGCGGCCGCGCTTCATCCTTTGGCAGCCAGTC-3′, and after digestion with *Xho* I and *Not* I, cloning into the psiCHECK2 vector (Promega, Madison, WI, USA) near 3′UTR of *Renilla* luciferase. Reporter construct for rs10759637 variant was made through point mutation (C/A) with primeSTAR using primers 5′-CAGCCTGTTGTCTCAAGCCAAGGAGTC-3′ (forward) and 5′-GACTCCTTGGCTTGAGACAACAGGCTG-3′ (reverse). Empty vector psiCHECK2 was used as negative control. Three microRNA mimics (hsa-miR-29a, 5′- UAGCACCAUCUGAAAUCGGUUA-3′; hsa-miR-29b, 5′-UAGCACCAUUUGAAAUCAGUGUU-3′ and hsa-miR-29c, 5′-UAGCACCAUUUGAAAUCGGUUA-3′) and one non-specific microRNA (miR-NC, 5′-UUG UACUACACAAAAGUACUG-3′) as negative control were synthetized from GenePharma, Shanghai China. Human bronchial epithelial cell line 16HBE (1.0 × 10^5^ cells) was cotransfected with wild or variant rs10759637 report vector (400 ng) and microRNA (40pmol miRNA) using Lipofectamine^™^ 2000 (Invitrogen). Luciferase activity was measured with Dual-Luciferase Reporter Assay System (Promega) on Envision 2104 Multilabel Reader (PerkinElmer). Every treatment was set three replications and three independent experiments were performed.

Real-time quantitative RT-PCR {#s4_5}
-----------------------------

We quantified transcript level of *SLC31A1* in lung cancer tissues from 47 patients using real-time quantitative RT-PCR assay. Total RNA was extracted from tumorous lung tissues with RNeasy Plus Mini Kit (QIAGEN, Hilden, Germany) and was then reverse transcribed into cDNA with PrimeScript RT Master Mix (TaKaRa, Dalian, China) using primers 5′-GAGAGAGCCTGCTGCGTAAG-3′ (forward) and 5′-AATGCAGAGGTACCCGTTGT-3′ (reverse). qRT-PCR was performed with SYBR^®^ Premix Ex Taq Kit (Takara) on an Applied Biosystems 7900HT. We measured the expression of β-actin as internal control using primers 5′-CAGAGCCTCGCCTTTGCC-3′ (forward) and 5′-ATGCCGGAGCCGTTGTCG-3′ (reserve). Every sample was set in triplicate. Expression of *SLC31A1* was normalized to β-actin with **∆∆**C~T~ method.

Statistical analysis {#s4_6}
--------------------

We used Pearson χ^2^ tests to examine deviations of genotype frequencies from those expected under HWE, and to test differences in the distributions of genotypes between patient groups with divergent clinical phenotypes or outcomes. We used the PHASE version 2.1 program to estimate haplotypes from the genotype data \[[@R43]\], and constructed the linkage disequilibrium (LD) plots using Haploview (<http://www.broadinstitute.org/haploview>), in which pairwise linkage disequilibrium relations among SNPs were examined using *D*′ and *r*^2^. We measured the association between genetic variants and dichotomous clinical phenotypes or outcomes by calculating odds ratios (OR) and their 95% confidence intervals (CIs) in unconditional logistic regression analysis, with adjustment of gender, age, smoking status, ECOG performance status, TNM status, histological types, and treatment regimen. Haplotype-based genetic association analysis was performed using Haplo.stats package in R-plus (available at <http://cran.r-project.org/web/packages/haplo.stats.index.html>; Version: 1.6.8). For each SNP, three different genetic models (dominant, recessive and additive) were analyzed, and the model with lowest *P* values was considered the best-fitting model. Under-dominant model was also analyzed for rs4979223 and rs10759637. The association between genetic variant and survival data (overall survival and progression-free-survival) was calculated by log-rank test with adjustment for covariates. The multivariate Cox proportional hazards regression was used for calculating the hazard ratios (HR) and 95% CI, Kaplan-Meier method was used to plot survival curve. All the statistical analysis was performed by SPSS (version 20). We use the two-side test for all *P* values. A *P* values \< 0.05 was considered statistically significant. To account for the issue of multiple testing of SNPs, we used SNPSpD to correct the significance threshold taking into account LD between polymorphisms \[[@R44]\].

SUPPLEMENTARY MATERIALS TABLES {#s5}
==============================
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